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Abstract:
Cultured human bone marrow mesenchymal cells (MSCs) have immunomodulatory and tissue regenerative properties. 
This report summarizes the result of post-transplant treatment with MSCs of a 26-year-old patient with aplastic anemia 
complicated by invasive sino-orbital aspergillosis. The patient was treated with MSCs to benefit from the dual effects of 
MSCs in immune reconstitution: suppression against alloreactive T cells and facilitation of the re-engraftment process. 
The patient did not develop acute or chronic graft-versus-host disease. The aspergillus infection healed completely. The 
engraftment failure was also ended without any complications. During his last visit in his fourth year after transplantation, 
the patient was in hematological remission. Human bone marrow-derived MSCs seem to have an important role in 
preventing or overcoming immunological complications in patients who undergo stem cell transplantation.    
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Özet:
Kemik iliği kaynaklı mezenkimal kök hücrelerin (MKH) immun düzenleyici ve doku tamir edici özellikleri vardır. 
Bu yazıda komplike invaziv sino-orbital aspergillozu olan 26 yaşındaki aplastik anemili olguda post transplant MKH 
uygulanması rapor edilmiştir. MKH ile tedavi edilen hastada MKH’lerin immun yeniden yapılanma üzerine çift yönlü 
etkisinden faydalanılarak; alloreaktif T hücreleri suprese edilmesi ve yamalanmanın kolaylaştırılması amaçlanmıştır. 
Komplike hastada akut ve kronik graft versus host hastalığı gelişmedi. Aspergilloz enfeksiyonu ve engraftmant yetmezliği 
komplikasyonsuz düzeldi. Takip eden visitlerinde hasta dördüncü yılında hematolojik remisyondadır. Kök hücre 
transplantasyonu yapılan hastalarda insan kemik iliği kaynaklı MKH’lerin uygulanması immunolojik komplikasyonlardan 
korunma ve önlenmesinde önemli role sahiptir. 
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Introduction
The infectious complications and immune dysfunction 
after human hematopoietic stem cell transplantation (HSCT) 
can activate acute graft-versus-host disease (GvHD) among 
patients undergoing HSCT [1]. The restoration of immune 
function is critical in effective treatment of invasive fungal 
infection and prevention of acute GvHD in these patients [2]. 
Mesenchymal stem cells (MSCs) are capable of regulating 
immune function and supporting marrow stroma [1,2,3,4,5]. 
Here we present a patient with very severe aplastic anemia 
and invasive aspergillosis who was successfully treated with 
hemopoietic stem cells from a sibling donor and MSCs from 
original and third-party donors.
Case Presentation 
A 26-year-old male patient with aplastic anemia was 
admitted to our center with fever, periorbital swelling, 
periorbital pain, and bloody nasal discharge. The patient had 
been diagnosed with severe aplastic anemia 10 days before, 
when the bone marrow examination (aspiration and biopsy) 
was compatible with severe idiopathic aplastic anemia 
(bone marrow cellularity of <10%). Empirical ceftazidime 
initiated for infection control was ineffective. Nasal and 
right periorbital erythema had developed 3 days before 
admission. On physical examination, fever of 38.5 °C, nasal 
and right periorbital erythema, and right periorbital swelling 
were detected. Ecchymosis and petechial lesions over the 
lower limbs were also present. Examination of the eyes was 
normal and no neurological abnormalities were detected. His 
hematological test revealed pancytopenia (WBC: 0.33x109/L, 
Hb:7 g/L, Plt:19x109/L). The percentages of lymphocytes, 
neutrophils, and eosinophils in the peripheral blood were 
91%, 1.9%, and 2.4% of total nuclear cells, respectively. 
The percentage of reticulocytes in the peripheral blood 
was 0.13% of erythrocytes. Peripheral blood smear revealed 
normochromic and normocytic erythrocytes and decreased 
leukocytes (mostly lymphocytes) and platelets. Serologic tests 
for antibodies to hepatitis B and C virus, cytomegalovirus, 
Epstein-Barr virus, and human immunodeficiency viruses 1 
and 2; serological tests for antinuclear antibodies; and a direct 
Coombs’ test were all negative. Biochemical tests revealed 
normal vitamin B12, folic acid, and serum iron. Computed 
tomography of the paranasal sinuses demonstrated a space-
occupying lesion of the right maxillary and ethmoid sinus 
region. Histopathology showed numerous PAS-stained 
Aspergillus hyphae without tissue invasion. Tissue culture 
revealed Aspergillus fumigatus.
The patient was a student. At the time of admission, he 
reported that he had not used any drugs or been exposed to 
any known chemicals recently. 
Voriconazole administration was started with limited 
clinical benefit (12 mg/kg/day). However, 20 days later, the 
patient developed fever and flare of nasal discharge. 
The First Transplant
A human leukocyte antigen (HLA)-compatible sibling 
bone marrow donor was available for transplantation. 
Hence, the patient underwent non-myeloablative allogeneic 
peripheral HSCT with a conditioning regimen including 
antithymocyte globulin (5 mg/kg/day for 3 days) and 
cyclophosphamide (50 mg/kg/day for 4 days). Five million 
cells per kilogram of CD34 cells were infused from the HLA-
matched sibling donor. Prophylaxis against GvHD was given 
with cyclosporine and methotrexate. Naturally, the patient 
was at high risk of GvHD because of the active fungal 
infection. For use prior to the possible onset of acute GvHD, 
human bone marrow MSCs, cultured ex vivo, were obtained 
from his original donor under good manufacturing practice 
conditions (Thanks to Prof. Dr. Ercüment Ovalı).
Following peripheral HSCT, neutrophil engraftment 
occurred on day +16. However, platelet recovery was not 
complete until day +32. Culture-expanded MSCs were 
infused on day +32 to the patient for hematopoietic support 
and their immunosuppressive effect to prevent acute GvHD. 
The MSC dose used was 1x106/kg. Platelets engrafted within 
10 days following MSC infusion. On day +60, complete 
peripheral blood count revealed the following: Hb, 8 g/L; 
WBC, 2.2x109/L (30% neutrophils, 68% lymphocytes, 2% 
monocytes); Plt, 70x109/L. A chimerism study revealed 
100% donor T-cell chimerism in the peripheral blood. He 
had no cytopenia or evidence of acute GvHD on days +90 
and +180. No early or late adverse events were demonstrated 
after MSC infusion. There was no improvement of the 
patient’s fungal infection after MSC infusion.
Second Transplant
The patient developed late donor-type engraftment failure 
in the eighth month. The use of immunosuppressive therapy 
including corticosteroids and cyclosporine for control of 
engraftment failure was ineffective. The patient therefore 
underwent a second transplant from the original donor 
using the same conditioning protocol. Human MSCs were 
obtained from an HLA-mismatched unrelated donor. This 
time, to promote engraftment, MSCs were given 4 h before 
stem cell infusion. The doses of MSCs and CD34 cells were 
0.8x106/kg and 6.43x106/kg, respectively. No lymphocyte 
depletion was performed because of absence of GvHD. Times 
to reach an absolute neutrophil count greater than 0.5x109/L 
and a platelet count greater than 50x109/L were 7 days and 
9 days, respectively. Graft function was normal on day +100 
of the second transplant. No early or late adverse events 
were demonstrated after MSC infusions. Informed consent 
was obtained from the patient for the applied procedures. 
Approval of the MSC infusion was also received from the 
National Regulatory Authorities. We are now following this 
patient as an outpatient in the post-transplant fourth year.
Discussion
Acute GvHD and graft failure/graft rejection remain 
the main clinical challenges in allogeneic HSCT. As an 
182
Turk J Hematol 2014;31:181-183 Özdoğu H, et al: MSCs, Immune Supression and Immune Reconstruction
important risk factor, active infections may influence 
the probability of incidence and severity of GvHD [1]. 
Post-transplant immunosuppressive therapy (mostly 
cyclosporine A and methotrexate) for prevention of GvHD 
may not be effective, especially in high-risk patients [1]. 
In addition, delayed engraftment or graft rejection may 
also be associated with severe infections [6]. McCann et 
al. [7] reported the poor outcome of graft failure patients 
(actuarial survival of 17%), where infection was an 
important contributory factor.
Human bone marrow MSCs are pluripotent cells that 
are able to home to damaged tissues and differentiate into 
various cell lineages such as adipocytes, fibrocytes, neural 
cells, and osteocytes [5]. They may also support the growth 
of bone marrow cells [3,4,5]. Several reports have shown 
the suppressive effects of MSCs on T cells, B cells, dendritic 
cells, and natural killer cell proliferation in vitro and in vivo 
[5]. For this reason, there has recently been great interest in 
the use of MSCs for the treatment of acute GvHD, but there 
is very little knowledge on prevention of GvHD with the 
use of MSCs [8,9,10,11]. In recent studies, MSCs have been 
shown to exert beneficial effects on hemopoietic recovery, 
prevention of graft rejection, and prevention or control of 
GvHD following allogeneic HSCT [12,13]. 
Fast engraftment was vital for our patient with active 
infection while he was undergoing transplantation. Thus, we 
decided to culture MSCs from the original donor, although 
we were not able to co-infuse MSCs with stem cells due 
to technical reasons during the first HSCT. We did MSC 
infusion on day +32 in order to at least prevent acute GVHD. 
Engraftment occurred as we wanted, with no GVHD, and the 
patient recovered quickly.
A second marrow transplant is the treatment of choice 
for aplastic anemia patients with no engraftment or graft 
rejection unresponsive to immunosuppressive therapy 
after HSCT [7]. We observed severe destruction of 
engrafted bone marrow cells, unresponsive to filgrastim 
and efficient immunosuppressive treatment, in the eighth 
month. Therefore, we decided to give the patient a second 
HSCT. To accelerate engraftment of the second allograft, 
co-infusion of a second dose of MSCs was planned [8]. 
This time, to prevent delay in infusion of MSCs, bone 
marrow MSCs from an HLA-mismatched unrelated donor 
were used based on the literature knowledge on this issue 
[9,10]. Successful and sustained engraftment occurred 
without any complications. 
Although a definitive conclusion cannot be made for 
MSCs’ usage, we think that MSCs allowed us to obtain a 
positive outcome from the point of view of the literature 
knowledge as discussed below. It has been reported that 
MSC infusion together with allogeneic hematopoietic stem 
cells resulted in fast engraftment of neutrophils and platelets 
[11]. Further support for the enhancement of hematopoietic 
recovery was presented by Le Blanc et al. [8]. They showed 
that MSCs promoted donor cell engraftment in patients with 
primary or secondary graft failure. It was also reported that 
MSC treatment suppressed acute GvHD in transplanted 
patients, who had better overall survival than patients in 
the control group [12]. Other investigators supported this 
observation [9,10].  
MSCs seem to be a promising treatment option for stem 
cell recipients who need fast hematopoietic recovery owing 
to co-morbidity. 
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